Teleflex Receives FDA 510(k) Clearance for Nylus™ PICC with Semprus Sustain™ Technology

  Teleflex Receives FDA 510(k) Clearance for Nylus™ PICC with Semprus Sustain™

Business Wire

LIMERICK, Pa. -- November 14, 2012

Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices
for critical care and surgery, has announced that its Semprus BioSciences
subsidiary has been granted 510(k) clearance for the Company’s innovative
vascular access catheter, the Nylus™ Peripherally Inserted Central Catheter
(PICC) with Semprus Sustain™ Technology. The Nylus PICC is indicated to
provide peripheral access to the central venous system for infusion,
intravenous therapy, blood sampling, central venous pressure monitoring and
power injection of contrast media. The FDA clearance follows the product’s
European market clearance in July, 2012.

The Nylus PICC uses a long-lasting polymer surface modification designed to
reduce the attachment of platelets and blood proteins at the surface of the
medical device. This provides benefits to the patient, the caregiver and the
health care system. The Nylus PICC has been shown to reduce platelet adhesion
and thrombus accumulation by 99% in both in vitro and acute animal testing.^1

“Teleflex is pleased to obtain FDA clearance for the Nylus PICC, which is the
first generation of the Semprus Sustain platform technology to move through
the FDA 510(k) process,” said Benson Smith, Chairman, President and CEO of
Teleflex Incorporated. “We continue to be excited about the technology’s
potential to reduce thrombus-related complications for patients in a variety
of applications.”

“With both U.S. and European market clearance, we are advancing a new standard
of care for PICC catheters, in which improved patient outcomes and lower
health care costs creates a win-win situation for patients and the healthcare
delivery system,” said David L. Lucchino, VP and co-founder of Semprus

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range
of procedures in critical care and surgery. Our mission is to provide
solutions that enable healthcare providers to improve outcomes and enhance
patient and provider safety. Headquartered in Limerick, PA, Teleflex employs
approximately 11,100 people worldwide and serves healthcare providers in more
than 130 countries. Additional information about Teleflex can be obtained from
the company's website at

Forward-Looking Statements

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any forward-looking
statements contained herein are based on our management's current beliefs and
expectations, but are subject to a number of risks, uncertainties and changes
in circumstances, which may cause actual results or company actions to differ
materially from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report on
Form 10-K.

Teleflex, Nylus, Semprus, and Semprus Sustain are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates. ©2012 Teleflex
Incorporated. 2012-1538

1 In vitro and in vivo data on file.


Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
Press spacebar to pause and continue. Press esc to stop.